Patents by Inventor Yuriko Fukata

Yuriko Fukata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6627194
    Abstract: Activated immunoglobulin which is useful as an eosinophilia-suppressing agent, immunomodulating agent, therapeutic agent for autoimmune diseases, anfiinflammatory agent and antiallergic agent is obtained by admixing immunoglobulin with a histamine component and then substantially or completely removing the histamine component. The histamine component may be removed or separated by dialysis, gel filtration, adsorption chromatography, ion exchange chromatography, or affinity chromatography. The method imparts pharmacological activity which is not inherently available in immunoglobulin of the natural type to immunoglobulin. The activated immunoglobulin of the present invention has an immunomodulating action which is clearly different from that of conventional immunosuppressive agents.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: September 30, 2003
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Haruo Yoshii, Mitsuru Naiki, Yuriko Fukata
  • Patent number: 6566386
    Abstract: In the present invention, pharmaceutical compositions containing a histamine-added gamma-globulin as an effective component are used as an immunomodulating agent, a suppressive agent for eosinophilia, and as an antiinflammatory agent. The immunomodulating action is unexpectedly different from the action of conventional immunosuppressive agents. Accordingly, the compositions are useful as a pharmaceutical agent for the therapy of diseases associated with an abnormal immune system such as chronic articular rheumatism, systemic lupus erythematosus, multiple sclerosis, etc. and various types of immunodeficiency syndromes. In addition, the pharmaceutical compositions exhibit suppressive action upon hypereosinophilicity. They may be used as a therapeutic agent for infectious diseases, parasitic diseases, respiratory diseases, autoimmune diseases and eosinophilia caused by malignant tumors. The compositions are excellent antiinflammatory agents.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: May 20, 2003
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Haruo Yoshii, Yuriko Fukata
  • Publication number: 20020004058
    Abstract: In the present invention, pharmaceutical compositions containing a histamine-added gamma-globulin as an effective component are used as an immunomodulating agent, a suppressive agent for eosinophilia, and as an antiinflammatory agent. The immunomodulating action is unexpectedly different from the action of conventional immunosuppressive agents. Accordingly, the compositions are useful as a pharmaceutical agent for the therapy of diseases associated with an abnormal immune system such as chronic articular rheumatism, systemic lupus erythematosus, multiple sclerosis, etc. and various types of immunodeficiency syndromes. In addition, the pharmaceutical compositions exhibit suppressive action upon hypereosinophilicity. They may be used as a therapeutic agent for infectious diseases, parasitic diseases, respiratory diseases, autoimmune diseases and eosinophilia caused by malignant tumors. The compositions are excellent antiinflammatory agents.
    Type: Application
    Filed: April 23, 2001
    Publication date: January 10, 2002
    Inventors: Haruo Yoshii, Yuriko Fukata
  • Patent number: 5856113
    Abstract: Fragments of cell membrane of erythrocyte are used as an antigen for insolubilization in enzyme immunoassay to provide a highly sensitive, excellent quantitative method for measuring anti-erythrocyte antibody. The cell membrane fragments of erythrocyte are the residual membrane fraction after removal of soluble cytoplasm proteins which interfere with the absorbance analysis of enzyme-linked immunosorbent assay (ELISA). The cell membrane fragments of erythrocyte which are used as an antigen may be prepared by destroying the erythrocytes to obtain a cell membrane fragment fraction and a cytoplasm protein fraction. The two fractions may be separated or fractionated by gel filtration, ultrafiltration or centrifugation to isolate the cell membrane fragment fraction. A solution of the cell membrane fragments of erythrocyte is substantially transparent and is useful as an insolubilized antigen for ELISA. The antigen is shelf stable for extended periods when stored in a cool, dark location.
    Type: Grant
    Filed: July 31, 1996
    Date of Patent: January 5, 1999
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Haruo Yoshii, Yuriko Fukata
  • Patent number: 5780026
    Abstract: In the present invention, pharmaceutical compositions containing a histamine-added gamma-globulin as an effective component are used as an immunomodulating agent, a suppressive agent for eosinophilia, and as an antiinflammatory agent. The immunomodulating action is unexpectedly different from the action of conventional immunosuppressive agents. Accordingly, the compositions are useful as a pharmaceutical agent for the therapy of diseases associated with an abnormal immune system such as chronic articular rheumatism, systemic lupus erythematosus, multiple sclerosis, etc. and various types of immunodeficiency syndromes. In addition, the pharmaceutical compositions exhibit suppressive action upon hypereosinophilicity. They may be used as a therapeutic agent for infectious diseases, parasitic diseases, respiratory diseases, autoimmune diseases and eosinophilia caused by malignant tumors. The compositions are excellent antiinflammatory agents.
    Type: Grant
    Filed: August 8, 1994
    Date of Patent: July 14, 1998
    Assignee: Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Haruo Yoshii, Yuriko Fukata